GSK to re-appoint Deloitte as external auditor

GSK plc announces that, following a competitive tender process led by its Audit & Risk Committee, the Board has decided to re-appoint Deloitte LLP as external auditor from the financial year ending 31 December 2028.

Rhea-AI Filing Summary

GSK plc announces that, following a competitive tender process led by its Audit & Risk Committee, the Board has decided to re-appoint Deloitte LLP as external auditor from the financial year ending 31 December 2028. Deloitte was initially appointed for the financial year ended 31 December 2018.

As a Public Interest Entity, GSK is required to tender its statutory audit every 10 years and rotate auditor every 20 years. A resolution to re-appoint Deloitte with effect from the 2028 financial year will be put to shareholders for approval at the 2028 Annual General Meeting, with further details to appear in GSK’s 2026 Annual Report.

Key Figures

Audit tender frequency: every 10 years Audit rotation requirement: every 20 years Start of new Deloitte term: financial year ending 31 December 2028 +1 more

4 metrics

Audit tender frequency every 10 years Requirement for GSK as a Public Interest Entity to tender statutory audit

Audit rotation requirement every 20 years Requirement for GSK as a Public Interest Entity to rotate external auditor

Start of new Deloitte term financial year ending 31 December 2028 Planned effective year of Deloitte’s re-appointment as external auditor

Initial Deloitte appointment year financial year ended 31 December 2018 Year Deloitte was first appointed as GSK’s external auditor

Key Terms

Public Interest Entity, statutory audit, competitive tender process, Annual General Meeting

4 terms

Public Interest Entity regulatory

"As a Public Interest Entity, GSK is required to tender the statutory audit"

statutory audit regulatory

"GSK is required to tender the statutory audit every 10 years"

A statutory audit is an independent, legally required examination of a company's financial statements and accounting records performed by an external auditor to confirm they follow applicable laws and accounting standards. It matters to investors because it provides an official, third‑party check on the accuracy and completeness of financial reporting—like an independent inspector certifying a building’s safety—helping users of the accounts rely on the numbers for valuations, comparisons, and risk assessment.

competitive tender process financial

"after the conclusion of a competitive tender process led by the Audit & Risk Committee"

Annual General Meeting regulatory

"approval at the Company's 2028 Annual General Meeting"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did GSK (GSK) decide regarding its external auditor?

GSK’s Board decided to re-appoint Deloitte LLP as its external auditor from the financial year ending 31 December 2028, following a competitive tender process led by the Audit & Risk Committee, subject to shareholder approval at the 2028 Annual General Meeting.

When will Deloitte’s re-appointment as GSK (GSK) auditor take effect?

Deloitte’s re-appointment is intended to take effect from GSK’s financial year ending 31 December 2028. A resolution for this re-appointment will be presented to shareholders for approval at the company’s 2028 Annual General Meeting.

What audit tender and rotation rules apply to GSK (GSK)?

As a Public Interest Entity, GSK is required to tender its statutory audit every 10 years and rotate its external auditor every 20 years. The competitive tender concluding in Deloitte’s planned re-appointment reflects these regulatory obligations.

When was Deloitte first appointed as GSK (GSK) external auditor?

Deloitte was first appointed as GSK’s external auditor with effect from the financial year ended 31 December 2018. The new decision extends that relationship, subject to shareholder approval, from the 2028 financial year onward.

How will GSK (GSK) shareholders approve Deloitte’s re-appointment?

A resolution to re-appoint Deloitte as GSK’s external auditor with effect from the 2028 financial year will be put to shareholders for approval at the company’s 2028 Annual General Meeting, in line with corporate governance practices.

Where will more details on GSK (GSK) audit tender be provided?

Further details of GSK’s competitive audit tender process will be included in the company’s 2026 Annual Report. This report is expected to describe the tender approach and considerations behind the Board’s decision to retain Deloitte.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/17/2026 - 07:14 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2026

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

Issued: 17 July 2026, London UK

Audit tender conclusion

GSK plc today announces that, after the conclusion of a competitive tender process led by the Audit & Risk Committee, the Board has decided to re-appoint Deloitte LLP (Deloitte) as GSK's external auditor from the financial year ending 31 December 2028.

As a Public Interest Entity, GSK is required to tender the statutory audit every 10 years and rotate every 20. The Company initially appointed Deloitte as external auditor with effect from the financial year ended 31 December 2018.

A resolution to re-appoint Deloitte as GSK's external auditor with effect from the 2028 financial year will be put to GSK's shareholders for approval at the Company's 2028 Annual General Meeting.

Further details of this competitive tender process will be included in GSK's 2026 Annual Report.

V A Whyte

Company Secretary

17 July 2026

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: July 17, 2026

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc